Synthetic Macromolecular Antibiotic Platform for Inhalable Therapy Against Aerosolized Intracellular Alveolar Infections
Lung-based intracellular bacterial infections remain one of the most challenging infectious disease settings. For example, the current standard for treating Franciscella tularensis pneumonia (tularemia) relies on administration of oral or intravenous antibiotics that poorly achieve and sustain pulmonary drug bioavailability. Inhalable antibiotic formulations are approved and in clinical development for upper respiratory infections, but sustained drug dosing from inhaled antibiotics against alveolar intracellular infections remains a current unmet need. To provide an extended therapy against alveolar intracellular infections, we have developed a macromolecular therapeutic platform that provides sustained local delivery of ciprofloxacin with controlled dosing profiles. Synthesized using RAFT polymerization, these macromolecular prodrugs characteristically have high drug loading (16-17 wt % drug), tunable hydrolysis kinetics mediated by drug linkage chemistry (slow-releasing alkyllic vs fast-releasing phenolic esters), and, in general, represent new fully synthetic nanotherapeutics with streamlined manufacturing profiles. In aerosolized and completely lethal F.t. novicida mouse challenge models, the fast-releasing ciprofloxacin macromolecular prodrug provided high cure efficiencies (75% survival rate under therapeutic treatment), and the importance of release kinetics was demonstrated by the inactivity of the similar but slow-releasing prodrug system. Pharmacokinetics and biodistribution studies further demonstrated that the efficacious fast-releasing prodrug retained drug dosing in the lung above the MIC over a 48 h period with corresponding Cmax/MIC and AUC0-24h/MIC ratios being greater than 10 and 125, respectively; the thresholds for optimal bactericidal efficacy. These findings identify the macromolecular prodrug platform as a potential therapeutic system to better treat alveolar intracellular infections such as F. tularensis, where positive patient outcomes require tailored antibiotic pharmacokinetic and treatment profiles.
D. Das and J. Chen and S. Srinivasan and A. M. Kelly and B. Lee and H. Son and F. Radella and T. E. West and D. M. Ratner and A. J. Convertine and S. J. Skerrett and P. S. Stayton, "Synthetic Macromolecular Antibiotic Platform for Inhalable Therapy Against Aerosolized Intracellular Alveolar Infections," Molecular Pharmaceutics, vol. 14, no. 6, pp. 1988-1997, American Chemical Society (ACS), Jun 2017.
The definitive version is available at https://doi.org/10.1021/acs.molpharmaceut.7b00093
Materials Science and Engineering
Keywords and Phrases
bacterial infection; ciprofloxacin; Francisella tularensis; infectious disease; pulmonary drug delivery
International Standard Serial Number (ISSN)
Article - Journal
© 2017 American Chemical Society (ACS), All rights reserved.